IP Library Granted Patent US 9,271,973
Granted Patent B2
US 9,271,973 · App. 14/091,589 · Granted Mar 1, 2016

Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,271,973
App. No.
14/091,589
Granted
Mar 1, 2016
Kind
B2
Abstract

Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).

Claims (340)

1. A method for treating an external genital or perianal wart in a subject comprising:

(a) applying a 3.75% w/w imiquimod pharmaceutical cream formulation to a dermatological area of the subject having the wart; and

(b) allowing the 3.75% imiquimod cream formulation to remain in contact with the dermatological area for a sufficient time following the application whereby an effective amount of the imiquimod composition penetrates the dermatological area; and

wherein the 3.75% w/w imiquimod cream formulation is applied to the dermatological area of the subject once daily for up to 8 consecutive weeks or until clearance is observed, whichever occurs earlier, to treat the wart.

2. The method of claim 1 , wherein imiquimod is the sole active pharmaceutical ingredient in the 3.75% w/w imiquimod cream formulation applied to the dermatological area of the subject.

3. The method of claim 1 , wherein the 3.75% w/w imiquimod cream formulation further comprises a pharmaceutically acceptable vehicle.

4. The method of claim 3 , wherein the pharmaceutically acceptable vehicle comprises a member selected from the group consisting of a fatty acid, an emollient, an emulsifier, a thickener, a preservative, a humectant, water, or a combination thereof.

5. The method of claim 4 , wherein the fatty acid is selected from the group consisting of isostearic acid, linoleic acid, oleic acid, super purified oleic acid, and a combination thereof.

6. The method of claim 5 , wherein the fatty acid is isostearic acid.

7. The method of claim 4 , wherein the fatty acid is present in an amount of between about 5% to about 25% by weight.

8. The method of claim 4 , wherein the emollient is selected from the group consisting of cetyl alcohol, stearyl alcohol, petrolatum, and a combination thereof.

9. The method of claim 4 , wherein the emollient is present in an amount of between about 5% to about 10% by weight.

10. The method of claim 4 , wherein the emulsifier is selected from the group consisting of polysorbate 60, sorbitan monostearate, and a combination thereof.

11. The method of claim 4 , wherein the emulsifier is present in an amount of between about 2% to about 6% by weight.

12. The method of claim 4 , wherein the preservative is selected from the group consisting of methylparaben, propylparaben, benzyl alcohol, and a combination thereof.

13. The method of claim 4 , wherein the humectant is glycerin.

14. The method of claim 4 , wherein the water is present in an amount of between about 45% to about 85% by weight.

15. The method of claim 3 , wherein the pharmaceutically acceptable vehicle consists of isostearic acid, cetyl alcohol, stearyl alcohol, white petrolatum, polysorbate 60, sorbitan monostearate, glycerin, xanthan gum, water, benzyl alcohol, methylparaben, and propylparaben.

16. The method of claim 1 , wherein the 3.75% w/w imiquimod cream formulation is selected from the group of 3.75% imiquimod formulations set forth in the tables below:

Excipients

% w/w

% w/w

% w/w

% w/w

% w/w

% w/w

Isostearic Acid

20.00

20.00

25.00

18.75

20.00

21.25

Cetyl alcohol

4.00

2. 20

2.20

2.20

2.20

2.20

Stearyl alcohol

2.40

3.10

3.10

3.10

3.10

3.10

White

3.40

3.00

3.00

5.00

5.00

3.75

petroleum

Polysorbate 60

3.80

3.40

3.40

3.00

3.40

3.40

Sorbitan

1.00

0.60

0.60

1.00

0.60

0.60

Monostearate

Glycerin

3.00

2.00

2.00

5.00

5.00

5.00

Xanthan gum

0.70

0.50

0.50

0.50

0.50

0.50

Purified water

55.73

59.23

54.23

55.48

54.23

54.23

Benzyl alcohol

2.00

2.00

2.00

2.00

2.00

2.00

Methylparaben

0.20

0.20

0.20

0.20

0.20

0.20

Propylparaben

0.02

0.02

0.02

0.02

0.02

0.02

Imiquimod

3.75

3.75

3.75

3.75

3.75

3.75

Total:

100.00

100.00

100.00

100.00

100.00

100.00

Excipients

% w/w

% w/w

% w/w

% w/w

% w/w

% w/w

Isostearic Acid

20.00

20.00

20.00

25.00

18.75

25.00

Cetyl alcohol

2.20

2.20

2.20

2.20

2.20

2.70

Stearyl alcohol

3.10

3.10

3.10

3.10

3.10

3.80

White

3.00

6.00

6.00

3.00

5.00

3.00

petroleum

Polysorbate 60

3.40

3.40

3.00

3.40

3.00

3.40

Sorbitan

0.60

0.60

1.00

0.50

1.00

0.60

Monostearate

Glycerin

2.00

5.00

5.00

2.00

5.00

2.00

Xanthan gum

0.50

0.50

0.50

0.50

0.50

0.50

Purified water

59.23

53.23

53.23

54.23

55.48

53.03

Benzyl alcohol

2.00

2.00

2.00

2.00

2.00

2.00

Methylparaben

0.20

0.20

0.20

0.20

0.20

0.20

Propylparaben

0.02

0.02

0.02

0.02

0.02

0.02

Imiquimod

3.75

3.75

3.75

3.75

3.75

3.75

Total:

100.00

100.00

100.00

100.00

100.00

100.00

Excipients

% w/w

% w/w

% w/w

% w/w

% w/w

% w/w

Isostearic Acid

25.00

20.00

20.00

20.00

20.00

 21.00

Cetyl alcohol

2.20

4.00

2.20

2.20

2.20

 2.20

Stearyl alcohol

3.10

2.40

3.10

3.10

3.10

 3.10

White

3.00

3.40

5.00

3.00

5.00

 5.00

petroleum

Polysorbate 60

3.40

3.80

3.40

3.40

3.40

 3.40

Sorbitan

0.60

1.00

0.60

0.60

0.60

 0.60

Monostearate

Glycerin

2.00

3.00

2.00

5.00

5.00

 5.00

Xanthan gum

1.00

0.70

0.50

0.50

0.50

 0.50

Purified water

53.73

55.73

57.23

56.23

54.23

 53.23

Benzyl alcohol

2.00

2.00

2.00

2.00

2.00

 2.00

Methylparaben

0.20

0.20

0.20

0.20

0.20

 0.20

Propylparaben

0.02

0.02

0.02

0.02

0.02

 0.02

Imiquimod

3.75

3.75

3.75

3.75

3.75

 3.75

Total:

100.00

100.00

100.00

100.00

100.00

 100.00.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: MEDICIS PHARMACEUTICAL CORPORATION
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043239/0675 →